The 24.7 Data Release includes updates to model studies.

Models

  • The JAX.IU.PITT_LOAD2.PrimaryScreen Study
    This study aims to develop and validate novel in vivo mouse models for late-onset Alzheimer’s disease (LOAD). Genetic variants were prioritized based on significance, biological function, sequence conservation, and differential expression in AD. These variants were introduced into B6J.APOE4.Trem2*R47H.hAPP background strains using CRISPR/Cas9 for knock-in or knock-out. RNA-Seq was used for genotyping and gene expression analysis. Key strains, including LOAD2.Adamts4-enhancerKO, LOAD2.Epha1-KI, and LOAD2.Il34-Y213, were evaluated at 4 and 12 months with 6 replicates per sex, plus age-matched controls.

  • The Jax.IU.Pitt_Verubecestat_5XFAD Study
    This update to the existing study includes new proteomics data. The study provides proteomics, NanoString messenger RNA counts, behavioral, imaging, and immunoassay data for 5XFAD mice treated with Verubecestat. The 5XFAD transgenic mice overexpress mutant human APP and  rapidly recapitulate major features of Alzheimer’s Disease amyloid pathology and may be useful models of intraneuronal Aβ-42 induced neurodegeneration and amyloid plaque formation. The study is conducted by the MODEL-AD Jax/IU/Pitt Preclinical Testing Core.